AbCellera Biologics Q4 Earnings Report: What Investors Need to Know
Benzinga Insights 8 months ago
Earnings
The Q4 earnings report for AbCellera Biologics (NASDAQ:ABCL) was released on Tuesday, February 24, 2026 at 04:05 PM.
Here's what investors need to know about the latest announcement.
Earnings
AbCellera Biologics beat estimated earnings by 83.33%, reporting an EPS of $-0.03 versus an estimate of $-0.18.
Revenue was up $39.80 million from the same period last year.
Earnings History Overview
The company missed on EPS by $0.02 in the last quarter, resulting in a 13.69% drop share price change the following day.
Here's a look at AbCellera Biologics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.17 | -0.14 | -0.15 |
| EPS Actual | -0.19 | -0.12 | -0.15 | -0.12 |
| Revenue Estimate | 6.45M | 6.58M | 7.12M | 7.58M |
| Revenue Actual | 8.96M | 17.08M | 4.24M | 5.10M |
To track all earnings releases for AbCellera Biologics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.